A Study of QLS31905 in Patients With Advanced Solid Tumors
This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.
Advanced Solid Tumors
DRUG: QLS31905
Dose limiting toxicities(DLTs), Number of participants experiencing DLTs According to NCI-CTCAE v.5.0ï¼ŒTo evaluate the safety and tolerability of QLS31905, 2 years|Maximum tolerated Dose(MTD), To evaluate the safety and tolerability of QLS31905, 2 years
Progression-free Survival (PFS), Progression free survival will be determined from investigator derived tumor assessments per RECIST 1.1., 2 years|Objective response rate (ORR), Objective Response Rate (ORR) is the percentage of CR+PR, 2 years|Disease control rate (DCR), Disease control Rate (DCR) is the percentage of CR+PR+SD, 2 years|adverse events (AE), To evaluate the safety and tolerability of QLS31905, 2 years|Cmax, Maximum concentration (Cmax) of the drug after administration, 2 years|AUC, The area under the curve (AUC) of serum concentration of the drug after the administration, 2 years
This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.